Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy.

Steinberg, Jonathan S.; Hochman, Judith S.; Morgan, Christopher D.; Dorian, Paul; Naylor, C. David; Théroux, Pierre; Topol, Eric J.; Armstrong, PW

doi:10.1161/01.cir.90.2.746

Cited by 47 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta-analysis of all available prospective studies, during the pre-thrombolytic era, on the use of SAECG after myocardial infarction showed that the SAECG predicted a sixfold increase in risk of arrhythmic events independent of left ventricular function, and an eightfold increase in risk of arrhythmic events independent of Holter results [91] . Thrombolysis reduced the frequency of SAECG abnormalities by 37% [92] and, in this setting, the predictive value of late potential was diminished [93] . More recent studies supported the concept that SAECG is an independent predictor of arrhythmic events after MI [86,93,94] .…”

Section: Late Potentialsmentioning

confidence: 67%

Task Force on Sudden Cardiac Death of the European Society of Cardiology

Priori

Aliot

Blomström‐Lundqvist

et al. 2001

European Heart Journal

771

445

View full text Add to dashboard Cite

Section: Late Potentialsmentioning

confidence: 67%

Task Force on Sudden Cardiac Death of the European Society of Cardiology

Priori

Aliot

Blomström‐Lundqvist

et al. 2001

European Heart Journal

771

445

View full text Add to dashboard Cite

“…Thus, thrombolytic therapy reduces the incidence of an abnormal SAECG in MI survivors. [91][92][93][94] SAECG performed early after MI is abnormal in 15% to 35% of patients. SCD or cardiac arrest occurs in 3.3% to 9% of these patients over the following 1 to 3 years.…”

Section: Signal-averaged Ecgmentioning

confidence: 99%

American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death

Goldberger¹,

Cain²,

Hohnloser³

et al. 2008

Circulation

777

361

View full text Add to dashboard Cite

“…[12][13][14] Moreover, it has been proposed that an open artery may increase tolerance to future coronary events and provide electric stability. 15,16 Previous studies with ICD recipients have focused on global coronary artery disease, with no difference between CTO or non-CTO arteries. With an increase in the number of ICD implantations for ischemic cardiomyopathy, a great number of patients with CTO can be expected.…”

Section: Clinical Perspective On P 154mentioning

confidence: 99%

Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients for Primary Prevention

Nombela‐Franco

Mitroi

Fernández‐Lozano

et al. 2012

Circ: Arrhythmia and Electrophysiology

141

View full text Add to dashboard Cite

Background-An implantable cardioverter-defibrillator (ICD) is the therapy of choice for primary prevention in patients with ischemia who are at risk for sudden cardiac death (SCD). One third of patients with significant coronary disease have chronic total coronary occlusion (CTO), which is associated with long-term mortality in patients with previous myocardial infarction. However, the impact of CTO on the occurrence of ventricular arrhythmias and long-term mortality in ICD recipients remains unknown. Methods and Results-All consecutive patients with coronary artery disease receiving ICD therapy for the prevention of SCD were included in the study. Among other characteristics, the existence of CTO was assessed. During follow-up, the occurrence of appropriate device delivery because of ventricular arrhythmias as well as mortality were noted. A total of 162 patients (mean age, 62Ϯ9 years; 93% men) with an ICD were included and followed for a median of 26 months (interquartile range, 12-42). At least 1 CTO was present in 71 (44%) patients. Appropriate device therapy was detected in 18% of the patients during the follow-up. The presence of CTO was associated with higher ventricular arrhythmia and mortality rates (log-rank test, Ͻ0.01). Multivariable analysis revealed that CTO was independently associated with appropriate ICD intervention (hazard ratio, 3.5; Pϭ0.003). Conclusions-In patients with ischemic heart disease receiving ICDs for primary prevention of SCD, CTO is an independent predictor for the occurrence of ventricular arrhythmias and has an adverse impact on long-term mortality. (Circ Arrhythm Electrophysiol. 2012;5:147-154.)

show abstract

Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy.

Abstract: Late thrombolytic therapy produced a more stable electrical substrate, which probably represents an important mechanism of mortality benefit.

Cited by 47 publications

References 37 publications

Task Force on Sudden Cardiac Death of the European Society of Cardiology

Task Force on Sudden Cardiac Death of the European Society of Cardiology

American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death

Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients for Primary Prevention

Contact Info

Product

Resources

About